Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $2.7 million.

  • Puma Biotechnology's Depreciation & Amortization (CF) fell 5.42% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 3.89%. This contributed to the annual value of $11.5 million for FY2024, which is 0.04% up from last year.
  • Puma Biotechnology's Depreciation & Amortization (CF) amounted to $2.7 million in Q3 2025, which was down 1.48% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Depreciation & Amortization (CF) ranged from a high of $3.0 million in Q4 2021 and a low of $2.4 million during Q3 2021.
  • For the 3-year period, Puma Biotechnology's Depreciation & Amortization (CF) averaged around $2.8 million, with its median value being $2.9 million (2023).
  • Per our database at Business Quant, Puma Biotechnology's Depreciation & Amortization (CF) soared by 54.02% in 2021 and then dropped by 17.63% in 2022.
  • Puma Biotechnology's Depreciation & Amortization (CF) (Quarterly) stood at $3.0 million in 2021, then decreased by 17.63% to $2.5 million in 2022, then increased by 17.77% to $2.9 million in 2023, then declined by 1.66% to $2.8 million in 2024, then decreased by 5.42% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.8 million for Q2 2025, and $2.8 million during Q1 2025.